The US FDA Approved United Therapeutics Product Tyvaso DPI™ for PAH and ILD

United Therapeutics Approval for Tyvaso DPI™
The US FDA approved United Therapeutics (UTHR) product Tyvaso DPI™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD) to improve exercise ability.

Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.